Healthcare >> Analyst Interviews >> November 6, 2000
European Pharmaceuticals Stocks
STEWART ADKINS is a graduate of Biochemistry and Genetics from Leeds
University. After spending two years at Ford Motor Company as a Product
Planning Analyst in the Truck Division he joined Lilly as a detail man.
Were it not for the demise of Opren he might have been there today.
However, after two years he joined Lehman Brothers' predecessor and
trained as a Pharmaceutical Analyst. He has worked in the City for over
17 years and has worked with Healthcare Team members, Jo Walton and Ian
Smith for most of that time. Well known amongst investors (rated in Top
three by Institutional Investor) and pharmaceutical companies alike,
their regular publication Pharmabulletin and ad hoc research,
PharmaPipelines and Valuation publications have achieved wide
circulation. Mr Adkins is married with two children. Profile
TWST: Could we start with a synopsis of the key sector developments over
the past six months; what have been the issues?
Mr. Adkins: I think the key sector developments actually have taken